In pancreatic cancer cell lines bearing Kras mutation, the interaction between KLF11 and SMAD3 is inhibited, and treatment with ERK pathway inhibitors such as U0126 (highly selective inhibitor of mitogen-activated protein kinase kinase 1/2–MEK1/2) can revert the Kras effect. Here, KRAS is linked to familial pancreatic carcinoma.